CLSDQ
Clearside Biomedical, Inc.
Price Chart
Latest Quote
$0.02
-0.09 (-81.82%)
Current Price
| Previous Close | $0.11 |
| Open | $0.31 |
| Day High | $0.31 |
| Day Low | $0.31 |
| Volume | 106 |
Stock Information
| Shares Outstanding | 5.23M |
| Total Debt | $61.61M |
| Cash Equivalents | $6.80M |
| Revenue | $3.33M |
| Net Income | $-26.00M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $105K |
| EPS (TTM) | $-5.11 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $55.39M |
| Sales | $3.33M |
| Income | $-26.00M |
| Book/sh | $-10.31 |
| Cash/sh | $1.30 |
| Employees | 32 |
Financial Ratios
| Quick Ratio | 2.55 |
| Current Ratio | 2.98 |
Returns & Margins
| ROA | -70.35% |
| Gross Margin | 88.07% |
| Operating Margin | -3502.49% |
Ownership
| Insider Ownership | 12.88% |
| Institutional Ownership | 3.39% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.00 |
| P/S | 0.03 |
| P/B | -0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.26 |
| SMA50 | $0.29 |
| SMA200 | $1.58 |
| RSI | 33.70 |
| ATR | 0.1040 |
| Shares Float | 4.59M |
| Short Float | 2.74% |
| Short Ratio | 3.86 |
| Volatility | 1.78 |
| Rel Volume | 0.02 |
Performance History
| Week | -93.33% |
| Month | -93.65% |
| Quarter | -95.99% |
| 6 Months | -98.08% |
| YTD | -97.33% |
| Year | -99.83% |
| 3 Years | -99.90% |
| 5 Years | -99.96% |
| 10 Years | -99.98% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $0.02 | 106 |
| 2026-06-16 | $0.11 | 1,100 |
| 2026-06-15 | $0.27 | 500 |
| 2026-06-12 | $0.28 | 0 |
| 2026-06-11 | $0.28 | 1,800 |
| 2026-06-10 | $0.30 | 2,600 |
| 2026-06-09 | $0.11 | 1,100 |
| 2026-06-08 | $0.01 | 11,400 |
| 2026-06-05 | $0.31 | 5,300 |
| 2026-06-04 | $0.34 | 0 |
| 2026-06-03 | $0.34 | 33,800 |
| 2026-06-02 | $0.34 | 1,900 |
| 2026-06-01 | $0.33 | 4,000 |
| 2026-05-29 | $0.32 | 0 |
| 2026-05-28 | $0.32 | 9,200 |
| 2026-05-27 | $0.31 | 1,100 |
| 2026-05-26 | $0.32 | 10,700 |
| 2026-05-22 | $0.31 | 5,500 |
| 2026-05-21 | $0.31 | 4,300 |
| 2026-05-20 | $0.31 | 300 |
| 2026-05-19 | $0.31 | 16,400 |
| 2026-05-18 | $0.31 | 8,200 |
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $149,000 | $355,000 | $204,000 | $0 |
| Cost Of Revenue | $149,000 | $355,000 | $204,000 | $0 |
| Total Revenue | $1,664,000 | $8,226,000 | $1,327,000 | $29,575,000 |
| Operating Revenue | $1,664,000 | $8,226,000 | $1,327,000 | $29,575,000 |
| Expenses | ||||
| Interest Expense | $9,779,000 | $9,360,000 | $3,339,000 | $0 |
| Total Expenses | $30,546,000 | $33,070,000 | $31,604,000 | $30,202,000 |
| Other Income Expense | $2,847,000 | $1,719,000 | $669,000 | $1,003,000 |
| Other Non Operating Income Expenses | $2,847,000 | $1,719,000 | $669,000 | $1,003,000 |
| Net Non Operating Interest Income Expense | $-8,317,000 | $-7,641,000 | $-2,670,000 | $0 |
| Interest Expense Non Operating | $9,779,000 | $9,360,000 | $3,339,000 | $0 |
| Operating Expense | $30,397,000 | $32,715,000 | $31,400,000 | $30,202,000 |
| General And Administrative Expense | $11,807,000 | $11,869,000 | $11,770,000 | $11,665,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-34,352,000 | $-32,485,000 | $-32,947,000 | $376,000 |
| Net Interest Income | $-8,317,000 | $-7,641,000 | $-2,670,000 | $0 |
| Interest Income | $1,462,000 | $1,719,000 | $669,000 | - |
| Normalized Income | $-34,352,000 | $-32,485,000 | $-32,947,000 | $376,000 |
| Net Income From Continuing And Discontinued Operation | $-34,352,000 | $-32,485,000 | $-32,947,000 | $376,000 |
| Total Operating Income As Reported | $-28,882,000 | $-24,844,000 | $-30,277,000 | $-627,000 |
| Net Income Common Stockholders | $-34,352,000 | $-32,485,000 | $-32,947,000 | $376,000 |
| Net Income | $-34,352,000 | $-32,485,000 | $-32,947,000 | $376,000 |
| Net Income Including Noncontrolling Interests | $-34,352,000 | $-32,485,000 | $-32,947,000 | $376,000 |
| Net Income Continuous Operations | $-34,352,000 | $-32,485,000 | $-32,947,000 | $376,000 |
| Pretax Income | $-34,352,000 | $-32,485,000 | $-32,947,000 | $376,000 |
| Interest Income Non Operating | $1,462,000 | $1,719,000 | $669,000 | - |
| Operating Income | $-28,882,000 | $-24,844,000 | $-30,277,000 | $-627,000 |
| Gross Profit | $1,515,000 | $7,871,000 | $1,123,000 | $29,575,000 |
| Per Share | ||||
| Diluted EPS | $-7.05 | $-7.95 | $-8.25 | $0.15 |
| Basic EPS | $-7.05 | $-7.95 | $-8.25 | $0.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-24,347,000 | $-23,058,000 | $-29,463,000 | $554,000 |
| Reconciled Depreciation | $226,000 | $67,000 | $145,000 | $178,000 |
| EBITDA (Bullshit earnings) | $-24,347,000 | $-23,058,000 | $-29,463,000 | $554,000 |
| EBIT | $-24,573,000 | $-23,125,000 | $-29,608,000 | $376,000 |
| Diluted Average Shares | $4,920,223 | $4,120,463 | $4,013,657 | $3,993,773 |
| Basic Average Shares | $4,920,223 | $4,120,463 | $4,013,657 | $3,899,465 |
| Diluted NI Availto Com Stockholders | $-34,352,000 | $-32,485,000 | $-32,947,000 | $376,000 |
| Research And Development | $18,590,000 | $20,846,000 | $19,630,000 | $18,537,000 |
| Selling General And Administration | $11,807,000 | $11,869,000 | $11,770,000 | $11,665,000 |
| Other Gand A | $11,807,000 | $11,869,000 | $11,770,000 | $11,665,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-38,855,000 | $-15,912,000 | $10,607,000 | $37,975,000 |
| Total Assets | $25,126,000 | $34,018,000 | $51,303,000 | $42,903,000 |
| Total Non Current Assets | $3,852,000 | $3,895,000 | $1,902,000 | $767,000 |
| Other Non Current Assets | $30,000 | $30,000 | $30,000 | $160,000 |
| Current Assets | $21,274,000 | $30,123,000 | $49,401,000 | $42,136,000 |
| Other Current Assets | $13,000 | $14,000 | $439,000 | $779,000 |
| Prepaid Assets | $734,000 | $722,000 | $704,000 | $921,000 |
| Receivables | $507,000 | $467,000 | $0 | $10,000,000 |
| Accounts Receivable | $507,000 | $467,000 | $0 | $10,000,000 |
| Cash Cash Equivalents And Short Term Investments | $20,020,000 | $28,920,000 | $48,258,000 | $30,436,000 |
| Cash And Cash Equivalents | $20,020,000 | $28,920,000 | $48,258,000 | $30,436,000 |
| Debt | ||||
| Total Debt | $703,000 | $1,013,000 | $1,285,000 | $675,000 |
| Long Term Debt And Capital Lease Obligation | $328,000 | $649,000 | $936,000 | $288,000 |
| Current Debt And Capital Lease Obligation | $375,000 | $364,000 | $349,000 | $387,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $63,981,000 | $49,930,000 | $40,696,000 | $4,928,000 |
| Total Non Current Liabilities Net Minority Interest | $59,187,000 | $43,117,000 | $34,913,000 | $288,000 |
| Other Non Current Liabilities | $52,167,000 | $42,468,000 | $33,977,000 | - |
| Derivative Product Liabilities | $6,692,000 | $0 | - | - |
| Current Liabilities | $4,794,000 | $6,813,000 | $5,783,000 | $4,640,000 |
| Current Deferred Liabilities | $0 | $75,000 | $205,000 | $0 |
| Payables And Accrued Expenses | $2,260,000 | $4,512,000 | $3,392,000 | $2,399,000 |
| Payables | $1,452,000 | $2,205,000 | $1,050,000 | $941,000 |
| Accounts Payable | $1,452,000 | $2,205,000 | $1,050,000 | $941,000 |
| Equity | ||||
| Common Stock Equity | $-38,855,000 | $-15,912,000 | $10,607,000 | $37,975,000 |
| Total Equity Gross Minority Interest | $-38,855,000 | $-15,912,000 | $10,607,000 | $37,975,000 |
| Stockholders Equity | $-38,855,000 | $-15,912,000 | $10,607,000 | $37,975,000 |
| Retained Earnings | $-355,275,000 | $-320,923,000 | $-288,438,000 | $-255,491,000 |
| Other | ||||
| Ordinary Shares Number | $5,105,225 | $4,190,056 | $4,042,655 | $3,981,528 |
| Share Issued | $5,105,225 | $4,190,056 | $4,042,655 | $3,981,528 |
| Tangible Book Value | $-38,855,000 | $-15,912,000 | $10,607,000 | $37,975,000 |
| Invested Capital | $-38,855,000 | $-15,912,000 | $10,607,000 | $37,975,000 |
| Working Capital | $16,480,000 | $23,310,000 | $43,618,000 | $37,496,000 |
| Capital Lease Obligations | $703,000 | $1,013,000 | $1,285,000 | $675,000 |
| Total Capitalization | $-38,855,000 | $-15,912,000 | $10,607,000 | $37,975,000 |
| Additional Paid In Capital | $316,343,000 | $304,948,000 | $298,984,000 | $293,406,000 |
| Capital Stock | $77,000 | $63,000 | $61,000 | $60,000 |
| Common Stock | $77,000 | $63,000 | $61,000 | $60,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $328,000 | $649,000 | $936,000 | $288,000 |
| Current Deferred Revenue | $0 | $75,000 | $205,000 | $0 |
| Current Capital Lease Obligation | $375,000 | $364,000 | $349,000 | $387,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,159,000 | $1,862,000 | $1,837,000 | $1,854,000 |
| Current Accrued Expenses | $808,000 | $2,307,000 | $2,342,000 | $1,458,000 |
| Net PPE | $3,822,000 | $3,865,000 | $1,872,000 | $607,000 |
| Accumulated Depreciation | $-1,146,000 | $-920,000 | $-853,000 | $-955,000 |
| Gross PPE | $4,968,000 | $4,785,000 | $2,725,000 | $1,562,000 |
| Leases | $476,000 | $476,000 | $476,000 | $667,000 |
| Construction In Progress | $1,870,000 | $2,590,000 | $527,000 | $0 |
| Other Properties | $597,000 | $869,000 | $1,117,000 | $369,000 |
| Machinery Furniture Equipment | $2,025,000 | $850,000 | $605,000 | $526,000 |
| Properties | $0 | $0 | $0 | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-25,675,000 | $-19,912,000 | $-13,611,000 | $-10,733,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-24,698,000 | $-18,135,000 | $-13,365,000 | $-10,733,000 |
| Cash Flow From Continuing Operating Activities | $-24,698,000 | $-18,135,000 | $-13,365,000 | $-10,733,000 |
| Operating Gains Losses | $-2,848,000 | - | $33,000 | $-998,000 |
| Investing Activities | ||||
| Capital Expenditure | $-977,000 | $-1,777,000 | $-246,000 | - |
| Investing Cash Flow | $-638,000 | $-1,777,000 | $-246,000 | $0 |
| Cash Flow From Continuing Investing Activities | $-638,000 | $-1,777,000 | $-246,000 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $16,389,000 | $1,666,000 | $566,000 | $23,283,000 |
| Financing Cash Flow | $16,436,000 | $414,000 | $31,333,000 | $23,782,000 |
| Cash Flow From Continuing Financing Activities | $16,436,000 | $414,000 | $31,333,000 | $23,782,000 |
| Net Common Stock Issuance | $16,389,000 | $1,666,000 | $566,000 | $23,283,000 |
| Common Stock Issuance | $16,389,000 | $1,666,000 | $566,000 | $23,283,000 |
| Net Other Financing Charges | - | $-1,350,000 | $30,638,000 | - |
| Other | ||||
| End Cash Position | $20,020,000 | $28,920,000 | $48,418,000 | $30,696,000 |
| Beginning Cash Position | $28,920,000 | $48,418,000 | $30,696,000 | $17,647,000 |
| Changes In Cash | $-8,900,000 | $-19,498,000 | $17,722,000 | $13,049,000 |
| Proceeds From Stock Option Exercised | $47,000 | $98,000 | $129,000 | $499,000 |
| Net Investment Purchase And Sale | $339,000 | $0 | $0 | $0 |
| Sale Of Investment | $17,250,000 | $0 | $0 | $0 |
| Purchase Of Investment | $-16,911,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-977,000 | $-1,777,000 | $-246,000 | $0 |
| Purchase Of PPE | $-977,000 | $-1,777,000 | $-246,000 | $0 |
| Change In Working Capital | $-1,677,000 | $720,000 | $11,236,000 | $-15,343,000 |
| Change In Other Working Capital | $-193,000 | $326,000 | $122,000 | $-5,155,000 |
| Change In Payables And Accrued Expense | $-1,433,000 | $614,000 | $694,000 | $681,000 |
| Change In Receivables | $-51,000 | $-220,000 | $10,420,000 | $-10,869,000 |
| Changes In Account Receivables | $-51,000 | $-220,000 | $10,420,000 | $-10,869,000 |
| Other Non Cash Items | $9,779,000 | $9,361,000 | $3,284,000 | - |
| Stock Based Compensation | $4,513,000 | $4,202,000 | $4,884,000 | $5,054,000 |
| Amortization Of Securities | $-339,000 | $0 | $0 | $0 |
| Depreciation Amortization Depletion | $226,000 | $67,000 | $145,000 | $178,000 |
| Depreciation And Amortization | $226,000 | $67,000 | $145,000 | $178,000 |
| Depreciation | $226,000 | $67,000 | $145,000 | $178,000 |
| Gain Loss On Investment Securities | $-2,848,000 | - | - | - |
| Gain Loss On Sale Of PPE | $0 | $0 | $33,000 | $0 |
| Net Income From Continuing Operations | $-34,352,000 | $-32,485,000 | $-32,947,000 | $376,000 |
| Repayment Of Debt | - | - | $0 | $0 |
| Issuance Of Debt | - | - | $0 | $0 |
| Interest Paid Supplemental Data | - | - | $0 | $0 |
| Net Issuance Payments Of Debt | - | - | $0 | $0 |
| Net Long Term Debt Issuance | - | - | $0 | $0 |
| Long Term Debt Payments | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
Fetched: 2026-02-02